Soaring Demand Set to Propel Minimal Residual Disease Testing Market to $2.96 Billion by 2029

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Expected CAGR for the Minimal Residual Disease Testing Market Through 2025?
The market size for minimal residual disease testing has seen swift expansion in the past few years. The size forecast shows growth from $1.59 billion in 2024 to $1.81 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.9%. Factors contributing to the growth during the historical period include progress in cancer research, the necessity of monitoring treatment, clinical evidence, regulatory backing, and the enhancement of patient outcomes.

What's the Projected Size of the Global Minimal Residual Disease Testing Market by 2029?
The market for minimal residual disease testing is set to expand rapidly in the forthcoming years. By 2029, it is projected to reach $2.96 billion, growing at a compound annual growth rate (CAGR) of 13.1%. The estimated growth during the forecast period is credited to various factors such as rising cancer rates, advancements in therapies, the popularity of precision medicine, a shift to early detection, and integration within the healthcare system. Notable developments expected in the forecast period include the incorporation of liquid biopsy methods, emphasis on early relapse detection, the use of MRD testing in clinical trials, its growing use in pediatric oncology, and collaborations for research and development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-testing-global-market-report

Top Growth Drivers in the Minimal Residual Disease Testing Industry: What's Accelerating the Market?
The rising incidence of cancer is anticipated to fuel the expansion of the minimal residual disease testing market. Cancer is a disease in which some body cells uncontrollably multiply and invade other parts of the body. Minimal residual disease testing, a highly accurate method for detecting cancer cells in the human body, is primarily used to identify cancer stages. This testing aids in the early detection and prevention of cancer in patients, thus stimulating the growth of the minimal residual disease testing market. For example, the American Cancer Society Inc., a nonprofit organization based in the United States, reported in 2022 that around 1.9 million new cases of cancer are forecasted to be diagnosed, resulting in an estimated 609,360 cancer-related deaths in the United States in 2022. Consequently, the surging incidence of cancer is fostering the growth of the minimal residual disease testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp

What Trends Will Shape the Minimal Residual Disease Testing Market Through 2029 and Beyond?
There is a conspicuous trend towards product innovations in the minimal residual disease testing market, with key players developing new products to maintain their competitive edge. For example, Twist Bioscience, a US-based company specialized in synthetic biology and genomics, rolled out the Twist MRD Panel in 2022. This move aims to propel research and development endeavors in the detection of minimal residual disease (MRD) in cancer screenings. The Twist MRD Panel is an adaptable array of genes designed for identifying extremely low levels of residual cancer cells in a patient's blood. Notably, the Twist MRD Panel has been engineered to allow for high flexibility and customization. It can be incorporated into traditional next-generation sequencing (NGS) processes and can identify minimal residual disease (MRD) in a mere five days.

What Are the Main Segments in the Minimal Residual Disease Testing Market?
The minimal residual disease testing market covered in this report is segmented -

1) By Test Type: DNA - Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users

Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp

Which Top Companies are Driving Growth in the Minimal Residual Disease Testing Market?
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

Which Regions Will Dominate the Minimal Residual Disease Testing Market Through 2029?
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9970

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.